Press releases

* (R) = Regulatory press releases

Dec 5, 2025

(R) Cantargia Provides Update on Overall Survival Data from TRIFOUR
Nov 19, 2025

(R) Cantargia Publishes Interim Report for January to September 2025
Nov 12, 2025

(R) Cantargia presents Nomination Committee ahead of 2026 AGM
Nov 5, 2025

Invitation to the Presentation of Cantargia’s Interim Report January-September 2025
Oct 23, 2025

Cantargia to Participate in Upcoming Conferences
Oct 2, 2025

(R) Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer
Oct 1, 2025

Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC
Sep 11, 2025

(R) Cantargia closes the acquisition of CAN10 by Otsuka
Aug 27, 2025

Cantargia granted important US patent for nadunolimab
Aug 21, 2025

(R) Cantargia publishes half-year report 2025
Aug 18, 2025

(R) Cantargia appoints Dr Hilde Steineger as Chief Executive Officer
Aug 12, 2025

Invitation to the presentation of Cantargia’s H1 2025 report
Jul 17, 2025

(R) Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)
Jul 16, 2025

Cantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer
Jul 15, 2025

(R) Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical
Jun 17, 2025

(R) Cantargia signs SEK 50 million financing facility agreement, extending cash runway into 2026 and providing operating flexibility to drive strategic plans
Jun 11, 2025

Cantargia’s nadunolimab antibody awarded US FDA Fast Track Designation
May 19, 2025

Cantargia publishes promising preclinical results highlighting CAN10's potential to inhibit vascular inflammation
May 15, 2025

(R) Bulletin from the Annual General Meeting in Cantargia AB
May 13, 2025

(R) Cantargia publishes interim report for the first quarter of 2025
May 12, 2025

Cantargia announces successful Phase 1 results: PK/PD data of subcutaneously administered CAN10 confirms every 4-week dosing choice in Phase 2
May 6, 2025

Cantargia’s announces publication of clinical data demonstrating potential of nadunolimab plus pembrolizumab in solid tumors
Apr 29, 2025

Invitation to the presentation of Cantargia’s interim report for Q1 2025
Apr 29, 2025

Cantargia announces selection of treatment resistant atopic dermatitis as second target indication for CAN10
Apr 28, 2025

Cantargia announces the publication of preclinical data highlighting nadunolimab's potential to counteract tumor-driven systemic immunosuppression
Apr 25, 2025

Cantargia presents promising preclinical results on anti-IL1RAP antibody-drug conjugate (ADC) at a major cancer conference
Apr 25, 2025

Cantargia presents association between nadunolimab and reduction of chemotherapy induced peripheral neuropathy (CIPN) at AACR
Apr 11, 2025

(R) Cantargia publishes Annual Report 2024
Apr 11, 2025

(R) Notice of annual general meeting in Cantargia AB (publ)
Apr 1, 2025

(R) Cantargia appoints Morten Lind Jensen as Chief Medical Officer
Mar 25, 2025

Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025.
Mar 25, 2025

Cantargia publishes an abstract on parallel anti-tumor activity and reduction of chemotherapy-induced neuropathy with nadunolimab
Mar 13, 2025

Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference
Mar 12, 2025

(R) First patient enrolled in Cantargia’s leukemia study with nadunolimab
Mar 10, 2025

Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited
Mar 6, 2025

Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference
Mar 5, 2025

(R) Cantargia reports promising CAN10 phase 1 data from first multiple dose cohort, and FDA and Key Opinion Leader feedback
Feb 21, 2025

(R) Cantargia publishes full year report for 2024
Feb 19, 2025

Cantargia to participate in Leerink Partners Global Healthcare Conference
Feb 13, 2025

Invitation to presentation of Cantargia’s Year-End report 2024
Feb 5, 2025

(R) Cantargia announces management changes
Jan 31, 2025

(R) Cantargia announces changes in number of shares and votes

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Interview with CEO VD Göran Forsberg (In Swedish) - 2024-12-10

BioStock

Redeye interviews CEO Göran Forsberg about the expansion of CAN10's phase 1 study (In Swedish) - 2024-12-02

Redeye

Interview with CEO Göran Forsberg about the expansion of CAN10's phase 1 study and rights issue (In Swedish) - 2024-12-02

Biostock

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer - 2024-10-14

Redeye

Interview with CEO Göran Forsberg about new results from the phase 1 study of CAN10 - 2024-08-12

Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer - 2024-06-28

Redeye

Interview with CEO Göran Forsberg about the new neuropathy results with nadunolimab in pancreatic cancer that will be presented at ASCO. (In Swedish) - 2024-05-24

Redeye

CEO Göran Forsberg interviewed on new results with CAN10 and external validation of IL-1 blockade during inflammatory disease. (In Swedish) - 2023-03-15

Redeye

Redeye interviews CEO Göran Forsberg about new results on nadunolimab and alleviation of neuropathy during chemotherapy. (In Swedish) - 2024-02-14

Redeye

COO Liselotte Larsson presents at Redeye Life Science Day - 2023-11-23

Redeye

CEO Göran Forsberg comments on the quarterly report (In Swedish) - 2023-11-10

Di TV

Interview with CEO Göran Forsberg about the directed share issue (In Swedish) - 2023-10-31

Redeye

Interview with CEO Göran Forsberg about new TRIFOUR results (In Swedish) - 2023-10-23

Redeye

CEO Interview, New results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AARC (In Swedish) - 2023-10-02

Redeye

CEO Interview, about expanded clinical pipeline and start of treatment in CAN10, for autoimmune diseases. (In Swedish) - 2023-09-05

Redeye

CEO interview, about the new readout from trials in non-small cell lung cancer - 2023-05-31

Redeye

CEO interview, Interim efficacy results nadunolimab (In Swedish) - 2023-05-31

Västra Hamnen Corporate Finance

CEO interview, Promising interim efficacy results for nadunolimab in lung cancer - 2023-05-26

Di TV

Cantargia presents updated interim results - 2023-05-26

Di TV

CEO interview, New clinical development strategy for nadunolimab in pancreatic cancer - 2023-05-17

Redeye

CEO interview, Positive results published at the AARC-conference 2023 - 2023-04-19

Redeye

CEO interview, New positive research results (In Swedish) - 2023-03-15

DiTV

CEO interview, CANFOUR new Biomarker data (In Swedish)- 2023-03-15

Redeye

CEO interview, TRIFOUR result (In Swedish)- 2023-02-23

Redeye

CEO interview, Redeye Life Science Day (In Swedish) - 2022-11-24

Redeye

CEO interview, Edison - 2022-06-24

Edison

CEO interview, Rights issue, Redeye (In Swedish) - 2022-06-22

Redeye

CEO interview, Edison - 2022-03-16

Edison

Panel discussion – Business development

Redeye

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB